A novel nasal irrigation therapy using topical vitamin D₃ for treating sinonasal inflammation, offering a natural, non-steroidal alternative to traditional treatments with potential for holistic respiratory care.
Topical Vitamin D₃ nasal irrigation presents a promising natural therapy for sinonasal inflammation conditions such as allergic rhinitis and chronic rhinosinusitis. This innovative approach uses high-volume nasal rinses to deliver active vitamin D₃ directly to the nasal mucosa, targeting inflammation and supporting mucosal immunity. By bypassing systemic metabolism, this method offers a more effective delivery of vitamin D's anti-inflammatory and barrier-restoring benefits compared to oral supplementation. This therapy aims to provide a scalable, low-toxicity alternative to synthetic antihistamines, aligning with trends in holistic and respiratory health care.
Key features:
The technology is currently at TRL 4, having been validated in preclinical models. A clinical trial is planned to further evaluate its safety and efficacy in human subjects, focusing on symptom improvement and immune biomarker changes.
UNC–Chapel Hill is a comprehensive public research university and the state’s flagship, pairing broad academic depth with a major academic health system. Industry partners access co‑located core facilities, sponsored research, and an on‑campus innovation hub that connects companies to faculty and advanced instrumentation. Integration with a major hospital system and statewide clinics enables patient access, clinical trials, and real‑world evidence collaborations. Minutes from Research Triangle Park, the university works within a dense corporate R&D ecosystem. Research is supported by strong competitive federal funding, including NIH and NSF, and a dedicated technology transfer office streamlines IP, licensing, MTAs, and startup formation.